Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Breast 1

Conditions

Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Breast Neoplasms 1

Interventions

Trastuzumab 9Paclitaxel 8Capecitabine 8trastuzumab deruxtecan 7Fulvestrant 7pertuzumab 5eribulin 5Gemcitabine 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5Doxorubicin 4Carboplatin 4Ado-Trastuzumab Emtansine 4sacituzumab govitecan 3ribociclib 3Vinorelbine 3Epirubicin 3Docetaxel 3selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2neratinib 2larotrectinib 2exemestane 2capivasertib 2abemaciclib 2Letrozole 2Fluorouracil 2Anastrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Alpelisib × Breast × Clear all
NCT02437318 2025-02-13

SOLAR-1

Novartis

Phase 3 Completed
572 enrolled 22 charts 1 FDA
BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡